NCT07248176Recruiting
Universal CAR-T Cell Therapy for MM
A Clinical Study on the Safety and Efficacy of Allogeneic CAR T Cells Targeting BCMA in the Treatment of Adult r/r Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 1 Dec 2025
Brief summary (registry, in English)
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 10 Apr 2025
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- Bioray Laboratories
- Diseases
- Multiple myeloma
- NCT number
- NCT07248176
What you commit to
- Study type: Interventional
- Planned participants: 6
- From 10 Apr 2025 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received allogeneic stem cell transplantation;
- Previous use of CAR-T cells or other genetically modified T cell therapies;
- Previously received targeted BCMA therapy;
Other illness
- History of other malignant tumors;
- Active autoimmune diseases requiring immunotherapy;
- Severe cardiovascular disease;
- Active infection;
- Clinically significant central nervous system (CNS) diseases or pathological changes.
Other
- Pregnant or breastfeeding women;
- Positive virology test;
Who the study is looking for
- Expected survival of at least 3 months;
- Subjects should have measurable disease that meets the IMWG 2016 criteria;
- Previously received at least two lines of prior anti-myeloma therapy ；
- Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
- BCMA positive；
- ECOG score 0-1；
- No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghi Tongji Hospital (Tongji Hospital of Tongji University) Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.